Alignment Healthcare, Inc. ALHC strengthened its 2026 outlook after a second quarter marked by higher membership, better-than-expected earnings and improving medical-cost performance. The first half also produced $106 million of adjusted EBITDA, up 60% year over year.
The trade-off is timing. Management plans additional clinical, artificial intelligence and expansion spending in the second half, with the heaviest impact in the third quarter. That leaves investors weighing durable operating momentum against a near-term step-down in profitability.
Here's a look at the company's solid track record of topping earnings estimates.
Image Source: Zacks Investment Research
ALHC’s Second-Quarter Results Beat Expectations
Second-quarter earnings were 17 cents per share, up from 7 cents a year earlier and 30.8% above the Zacks Consensus Estimate. Revenues increased 31.6% to $1.34 billion and topped the consensus mark by 2%.
Health plan membership reached about 294,100, up 31.5% year over year and above the prior guidance range of 288,000-290,000. Adjusted gross profit rose 35.3% to $182.9 million, lifting adjusted gross margin to 13.7% from 13.3%.
Raised Guidance Confirms ALHC’s Operating Momentum
Management raised the midpoint of its full-year guidance metrics after the first-half performance. The company now expects 2026 revenues of $5.195 billion-$5.225 billion and membership of 298,000-301,000.
Image Source: Zacks Investment Research
Adjusted gross profit is projected at $630 million-$650 million, while adjusted EBITDA is expected at $145 million-$163 million. Humana Inc. HUM offers relevant Medicare Advantage context, as it recently reaffirmed expectations for roughly 25% individual Medicare Advantage membership growth in 2026.
Third-Quarter Spending Tests ALHC’s Progress
The third-quarter outlook shows the cost of that growth agenda. ALHC expects adjusted EBITDA of $20 million-$30 million, versus $68.1 million in the second quarter, as Care Anywhere hiring, artificial intelligence projects and 2027 market-launch preparation accelerate.
Management expects only about 30% of full-year adjusted EBITDA to be generated in the second half, compared with roughly 40% in the prior year. Additional second-half investment is expected to reach the double-digit millions across medical costs and selling, general and administrative expenses.
AI Investment Could Expand ALHC’s Leverage
The newest version of ALHC’s AVA risk-stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the next 30 days. That targeting can help Care Anywhere teams direct clinical resources toward members with the highest near-term risk.
The company is also expanding automation across claims processing, chart preparation, risk adjustment and reconciliation. First-half adjusted selling, general and administrative expenses fell to 8.7% of revenues, improving 40 basis points year over year despite continued systems investment.
Medical-Cost Trends Remain the Key ALHC Variable
Adjusted medical benefit ratio improved 40 basis points year over year to 86.3%, the company’s lowest level since becoming publicly traded. Excluding the new-member final sweep, the ratio was 86.7% and remained favorable to guidance.
The third quarter is expected to bring a seasonally higher ratio because of greater new-member acuity, a flatter Part D cost slope and added clinical investment. UnitedHealth Group Incorporated UNH reported a second-quarter 2026 medical cost ratio of 86.7%, illustrating how medical-cost discipline remains central across large managed-care platforms.
ALHC’s Ratings Reflect Event-Driven Uncertainty
ALHC’s raised outlook provides a cushion against heavier spending, but the second-half mix leaves less room for execution errors in utilization management, hiring and technology implementation. The near-term case therefore depends on whether those investments translate into operating leverage without disrupting medical-cost control.
The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A, Value Score of B and VGM Score of A point to favorable growth and blended style characteristics, while the Momentum Score of D indicates weaker near-term price momentum. The combination supports a measured stance rather than a definitive call based on one quarter.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpAlignment Healthcare, Inc. (ALHC) : Free Stock Analysis Report
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
Humana Inc. (HUM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
